These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 18671476

  • 21. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [Abstract] [Full Text] [Related]

  • 22. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
    Matheron S, Descamps D, Boué F, Livrozet JM, Lafeuillade A, Aquilina C, Troisvallets D, Goetschel A, Brun-Vezinet F, Mamet JP, Thiaux C, CNA3007 Study Group.
    Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ, Talbird SE, Cohen C.
    Value Health; 2011 Apr; 14(5):657-64. PubMed ID: 21839403
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.
    d'Ettorre G, Mastroianni CM, Massetti AP, Lichtner M, D'Agostino C, Vullo V.
    AIDS; 2005 May 20; 19(8):841-2. PubMed ID: 15867503
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
    Munderi P, Walker AS, Kityo C, Babiker AG, Ssali F, Reid A, Darbyshire JH, Grosskurth H, Mugyenyi P, Gibb DM, Gilks CF, DART/NORA trial teams.
    HIV Med; 2010 May 20; 11(5):334-44. PubMed ID: 20136661
    [Abstract] [Full Text] [Related]

  • 32. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
    DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, Brothers CH, Hernandez J, Castillo SA, Bonny T, Lanier ER, Scott TR, CNA30024 Study Team.
    Clin Infect Dis; 2004 Oct 01; 39(7):1038-46. PubMed ID: 15472858
    [Abstract] [Full Text] [Related]

  • 33. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
    Sprenger HG, Langebeek N, Mulder PG, Ten Napel CH, Vriesendorp R, Hoepelman AI, Legrand JC, Koopmans PP, Bravenboer B, Ten Kate RW, Groeneveld P, Bierman W, van der Werf Ts, Gisolf E, Richter C.
    HIV Med; 2015 Feb 01; 16(2):122-31. PubMed ID: 25472825
    [Abstract] [Full Text] [Related]

  • 34. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND, Bader J, Lejone TI, Ringera I, Puga D, Glass TR, Klimkait T.
    Trop Med Int Health; 2015 Jul 01; 20(7):914-8. PubMed ID: 25782332
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H, Sedani S, Gartland M, ASSERT Team.
    Antivir Ther; 2013 Jul 01; 18(7):905-13. PubMed ID: 23899468
    [Abstract] [Full Text] [Related]

  • 37. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
    Orkin C, Stebbing J, Nelson M, Bower M, Johnson M, Mandalia S, Jones R, Moyle G, Fisher M, Gazzard B.
    J Antimicrob Chemother; 2005 Feb 01; 55(2):246-51. PubMed ID: 15608053
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
    Tan DH, Chan K, Raboud J, Cooper C, Montaner JS, Walmsley S, Hogg RS, Klein MB, Machouf N, Rourke SB, Tsoukas C, Loutfy MR, CANOC Collaboration.
    J Acquir Immune Defic Syndr; 2011 Sep 01; 58(1):38-46. PubMed ID: 21709570
    [Abstract] [Full Text] [Related]

  • 40. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
    Barrios A, Negredo E, Domingo P, Estrada V, Labarga P, Asensi V, Morales D, Santos J, Clotet B, Soriano V, EFADITE Study Group.
    Antivir Ther; 2005 Sep 01; 10(7):825-32. PubMed ID: 16312178
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.